** SPAM - Trenik Bijmy w Szcześciu żyjmy - SPAM ** %-)))

znam takich co do 200 dochodzili,teraz mogę powiedzieć że znam jednego co 400 je

U mnie lekko.. 200 mcg clena , 100 mcg t3 i 70 mg trena

No no na całego ta zabawa
480

Kowal dopijam kawe, jescze czekam na typa bo hajs mi musi oddać

Nie jadlem nigdy clenu i nie bede bo to nie zdrowe
























Swiruje z checia bym podjadl ale boje sie o serducho z tym nadcisnieniem

Gdzieś czytałem badania ,że leczniczo podawali chorym na serce 720 mcg clenu przez prawie rok.

chyba dawki pomyliłeś

Nie zaraz poszukam

chyba że jako adrenaline

prestarium sobie kup do apteczki koksa

Czemu, 3g testa też wbijają na tydzień i wiele innych ciekawych specyfików

Effect of clenbuterol on cardiac and skeletal muscle function during left ventricular assist device support.
George I, Xydas S, Mancini DM, Lamanca J, DiTullio M, Marboe CC, Shane E, Schulman AR, Colley PM, Petrilli CM, Naka Y, Oz MC, Maybaum S.
Source

Department of Surgery, Division of Cardiothoracic Surgery, Columbia College of Physicians and Surgeons, New York, New York 10032, USA. [email protected]
Abstract
BACKGROUND:

High-dose clenbuterol (a selective beta2-adrenergic agonist) has been proposed to promote myocardial recovery during left ventricular assist device (LVAD) support, but its effects on cardiac and skeletal muscle are largely unknown.
METHODS:

Seven subjects with heart failure (5 ischemic, 2 non-ischemic) were started on oral clenbuterol 5 to 46 weeks post-LVAD implantation and up-titrated to daily doses of 720 microg. The following procedures were performed at baseline and after 3 months of therapy: echocardiography at reduced support (4 liters/min); cardiopulmonary exercise testing; body composition analysis; and quadriceps maximal voluntary contraction (MVC). Myocardial histologic analysis was measured at device implantation and explantation.
RESULTS:

There were no serious adverse events or arrhythmias. Creatine phosphokinase (CPK) was elevated in 4 subjects, with no clinical sequelae. No change in ejection fraction was seen. End-diastolic dimension increased significantly (4.73 +/- 0.67 vs 5.24 +/- 0.66; p < 0.01), despite a trend toward increased LV mass. Body weight and lean mass increased significantly (75.5 +/- 17.9 vs 79.2 +/- 25.1 kg, 21.1 +/- 8.9 vs 23.6 +/- 9.7 kg, respectively; both p < 0.05). Exercise capacity did not change, but MVC improved significantly from 37.0 +/- 15.7 to 45.8 +/- 20.6 kg (p < 0.05). No significant change in myocyte size or collagen deposition was seen.
CONCLUSIONS:

Cardiac function did not improve in this cohort of LVAD patients treated with high-dose clenbuterol. However, clenbuterol therapy increased skeletal muscle mass and strength and prevented the expected decrease in myocyte size during LVAD support. Further study will clarify its potential for cardiac and skeletal muscle recovery.

PMID:
16962470
[PubMed - indexed for MEDLINE]